The US Food and Drug Administration approves Janssen Pharmaceutica's esketamine for treatment-resistant depression. The drug is the chemical cousin of ketamine, a powerful anesthetic and recreational drug, and the first major new depression treatment to be approved by the FDA in more than 30 years.
